Direct-to-Consumer Advertising of COX-2 Inhibitors: Effect on Appropriateness of Prescribing
- 1 October 2005
- journal article
- research article
- Published by SAGE Publications in Medical Care Research and Review
- Vol. 62 (5), 544-559
- https://doi.org/10.1177/1077558705279314
Abstract
Spending on direct-to-consumer advertising (DTCA) of prescription drugs has increased dramatically in the past several years. An unresolved question is whether such advertising leads to inappropriate prescribing. In this study, the authors use survey and administrative data to determine the association of DTCA with the appropriate prescribing of cyclooxygenase-2 (COX-2) inhibitors for 1,382 patients. Treatment with either a COX-2 or a traditional nonsteroidal anti-inflammatory drug (NSAID) was defined as appropriate or not according to three different definitions of gastrointestinal risk. Patients who saw or heard a COX-2 advertisement and asked their physician about the advertised drug were significantly more likely to be prescribed a COX-2 (versus a NSAID, as recommended by evidence-based guidelines) than all other patients. Findings also suggest that some patients may benefit from DTCA. The authors discuss the need for balanced drug information for consumers, increased physician vigilance in prescribing appropriately, and further study of DTCA.Keywords
This publication has 13 references indexed in Scilit:
- Influence of Patients’ Requests for Direct-to-Consumer Advertised AntidepressantsJAMA, 2005
- Economic Implications of Evidence-Based Prescribing for HypertensionJAMA, 2004
- Pharmaceutical Promotion, Advertising, And ConsumersHealth Affairs, 2003
- Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patientGastroenterology, 2001
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Health Spending In 1998: Signals Of ChangeHealth Affairs, 2000
- Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparisonThe Lancet, 1999
- Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: A randomized, controlled trialClinical Therapeutics, 1999
- A Chronic Disease Score with Empirically Derived WeightsMedical Care, 1995